<DOC>
	<DOCNO>NCT02673047</DOCNO>
	<brief_summary>This study describe prescription condition botulinum toxin Type A ( Botox® ) injection treatment urinary incontinence due neurogenic detrusor overactivity ( NDO ) idiopathic overactive bladder ( IOAB ) per standard care clinical practice France .</brief_summary>
	<brief_title>Observational Study Botulinum Toxin Type A Patients With Urinary Incontinence Associated With Overactive Bladder</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Urinary Bladder , Neurogenic</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Patients receive Botox® injection urinary incontinence . Patients reside France .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>